Weed, Inc. (OTC: BUDZ)

WEED, Inc. is a development-stage company focused on the cannabis and hemp industry, with ambitions to become a global leader in research, product development, and commercial cultivation. The company operates across multiple facets of the cannabis value chain, including genetic research, therapeutic product development, and real estate ventures tied to cannabis-friendly infrastructure. WEED, Inc. aims to leverage its intellectual property, proprietary strains, and strategic acquisitions to establish a seed-to-sale business model, encompassing everything from cultivation to branded consumer products. Its activities span both medical and recreational cannabis markets, with a long-term vision of addressing global demand through research-driven innovation and international expansion.

WEED, Inc. currently generates no revenue, as it remains in the pre-commercialization phase of its business plan. The company’s future revenue streams are expected to derive from several sources, including licensing proprietary cannabis strains, leasing cultivation facilities to licensed operators, selling cannabis-derived therapeutics, and developing infused beverages and other consumer products. Additional revenue may come from consulting services for governments, universities, and commercial growers, as well as real estate development tied to cannabis-friendly resorts and residential properties. The company’s business model relies on securing sufficient funding to transition from research and development to commercial operations, with a focus on high-margin intellectual property and branded products.

The company operates through the following segments.

• Cannabis Research and Development: This segment focuses on genetic mapping, strain development, and clinical research to create proprietary cannabis and hemp varieties. WEED, Inc. has completed pilot genomic studies and holds a collection of over 200 high-THC strains, including rare landrace varieties. The segment also encompasses therapeutic product development, with plans to conduct clinical trials in collaboration with academic institutions and international research partners. No commercial products have been launched, and further progress depends on additional funding.

• Real Estate and Infrastructure: This segment involves the acquisition and development of properties for cannabis-related uses, including cultivation, processing, and hospitality. WEED, Inc. owns a 43-acre waterfront property in New York, which includes unlimited water extraction rights and a wastewater management plant. The company plans to develop the site for hemp and infused beverage production, with long-term ambitions to build a cannabis-friendly luxury resort and condominium complex. The property is held through a wholly-owned subsidiary, Four Winds of Lake Erie, LLC.

• International Operations: This segment includes WEED, Inc.’s subsidiaries in Australia and Israel, which serve as gateways to emerging cannabis markets in Oceania and Asia. WEED Australia Ltd. operates the Cannabis Institute of Australia, a non-profit entity conducting research and educational services. WEED Israel Cannabis Ltd. was established to collaborate with Israeli institutions on clinical trials and product development, with a focus on meeting FDA-quality standards. Both subsidiaries are positioned to facilitate global research, regulatory compliance, and market expansion.

WEED, Inc. operates in the highly competitive and rapidly evolving cannabis industry, where it competes with established players in research, cultivation, and product development. Key competitors include multinational cannabis companies with advanced genetic libraries, pharmaceutical firms developing cannabis-based therapeutics, and real estate developers targeting cannabis-friendly properties. The company’s competitive advantages lie in its proprietary strain collection, including rare landrace varieties, and its strategic real estate assets, particularly the New York waterfront property with unique infrastructure. Additionally, its international subsidiaries provide access to markets with favorable regulatory environments, such as Israel and Australia, where cannabis research is more advanced. However, WEED, Inc. faces significant challenges, including regulatory uncertainty, funding constraints, and the need to commercialize its research before competitors do.

WEED, Inc. does not currently serve a commercial customer base, as its operations remain in the research and development phase. Its future customers are expected to include licensed cannabis dispensaries, pharmaceutical companies, beverage manufacturers, and organic growers seeking proprietary strains or cultivation infrastructure. The company also targets universities, government agencies, and non-profit organizations for research collaborations and educational services. In the long term, WEED, Inc. plans to serve global markets through its international subsidiaries, with a focus on regions where medical and recreational cannabis use is legalized.